# Assessment of the Type and Degree of Genomic Instability in Gliomas

## TL;DR

This study examines genomic instability in gliomas and finds that it contributes to tumor progression and could help predict patient outcomes.

## Contribution

The study identifies the specific patterns and clinical associations of genomic instability in gliomas using AP-PCR.

## Key findings

- Both microsatellite and chromosomal instability were present in all samples, contributing equally to genomic instability.
- Low overall instability, mainly microsatellite instability, was the dominant pattern in the cohort.
- Low genomic instability was linked to poorer survival in patients over 50 years old.

## Abstract

Glial brain tumours, including astrocytoma IDH (Isocitrate Dehydrogenase) mutant and glioblastoma IDH wild-type, are highly malignant brain tumours with poor clinical outcomes. Genomic instability, encompassing microsatellite (MIN) and chromosomal instability (CIN), drives tumour heterogeneity and evolution. In this study, genomic instability was analysed in 85 patients using AP-PCR (Arbitrarily Primed Polymerase Chain Reaction) by comparing tumour and normal tissue (blood) DNA profiles of the same patient. Both types of alterations were present in all analysed samples, contributing almost equally to the total level of genomic instability. The dominant pattern of genomic instability in our cohort was low overall instability, predominantly manifesting as low-degree microsatellite instability. A general decrease in genomic instability was observed with increasing tumour grade. Glioblastoma IDH wild-type was more prevalent in older patients, whereas astrocytoma IDH mutant predominated in younger individuals. Notably, low genomic instability (both MIN and CIN) was associated with poorer survival in patients over 50 years of age. Females, compared to males, exhibited higher MIN in grade 2 tumours and elevated CIN in grade 4 tumours. Our results confirm that genomic instability contributes to tumour progression, MIN being the pivotal factor, and could serve as a prognostic biomarker in malignant gliomas.